Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study
Martin J. van den Bent(Erasmus MC Cancer Institute), Johan M. Kros(Erasmus MC), Winand N.M. Dinjens(Erasmus MC), Anja Gijtenbeek(Radboud University Nijmegen), Warren Mason(Princess Margaret Cancer Centre), Anna K. Nowak(The University of Western Australia), Jaap C. Reijneveld(Amsterdam UMC Location University of Amsterdam), Catherine McBain(Unknown), Matthew Griffin(Nottingham University Hospitals NHS Trust), Michael Weller(University Hospital of Zurich), Sanjeev Gill(The Alfred Hospital), Walter Taal(Heidelberg University), Sarah Nuyens(European Organisation for Research and Treatment of Cancer), Thierry Lesimple, Thierry Gorlia(European Organisation for Research and Treatment of Cancer), Peter Hau(University Hospital Regensburg), Roelien H. Enting(University of Groningen), S. Pascoe(Plymouth Hospital), Pieter Wesseling(Radboud University Nijmegen), Susan Clenton(Weston Park Cancer Centre), Roger Stupp(Northwestern University), Sara Erridge(The University of Texas MD Anderson Cancer Center), Robert B. Jenkins(Dartmouth–Hitchcock Medical Center), Damien C. Weber(University Hospital of Geneva), Ulrich Herrlinger(University of Tübingen), Ken Aldape(The University of Texas MD Anderson Cancer Center), Marc Sanson(Centre National de la Recherche Scientifique), Olivier Chinot(Aix-Marseille Université), Brigitta G. Baumert(Kantonsspital Graubünden), Helen Wheeler(The University of Sydney), Wolfgang Wick(German Cancer Research Center), Alba A. Brandes(Istituto delle Scienze Neurologiche di Bologna), F. Dhermain(Institut Gustave Roussy), David Brachman(Barrow Neurological Institute), Roberta Rudà, Jean Français Baurain(Cliniques Universitaires Saint-Luc), Michael A. Vogelbaum, Vassilis Golfinopoulos(Champalimaud Foundation), Hendrikus J. Dubbink(Erasmus MC), Irene van Heuvel(Erasmus MC Cancer Institute), Paul M. Clément(Universitair Ziekenhuis Leuven)
Cited by 401
Related Papers
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
|Nature|2008|7.8k
<i>MGMT</i> Gene Silencing and Benefit from Temozolomide in Glioblastoma
|New England Journal of Medicine|2005|7.2k
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
Paraneoplastic anti– <i>N</i> ‐methyl‐ <scp>D</scp> ‐aspartate receptor encephalitis associated with ovarian teratoma
|Annals of Neurology|2007|2.5k